Drugs / 18F-FAZA
18F-FAZA
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00323076 | Sep 2006 → Feb 2019 | neuroendocrine neoplasm, renal cell carcinoma | AHS Cancer Control Alberta | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02802969 | Jul 2016 → Nov 2024 | skull base chordoma, spinal chordoma | Institut Curie | Completed | No outcome recorded |
| Phase 2 | NCT00771381 | Nov 2008 → Feb 2019 | breast neoplasm | AHS Cancer Control Alberta | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04395469 | May 2021 → Mar 2027 expected | pancreatic adenocarcinoma | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| — | NCT03418818 | Mar 2018 → Oct 2028 expected | sarcoma | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| — | NCT02496832 | Nov 2014 | metastatic neoplasm, pancreatic adenocarcinoma | University Health Network, Toronto | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18]F-FAZA | “A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck,...” NCT00323076 ↗ |
| Known as | 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole | “A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck,...” NCT00323076 ↗ |
| Known as | 18F-Fluoroazomycin arabinoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496832 ↗ |
| Modality | Diagnostic / imaging agent | “The PET tracer [18]F-FAZA can identify hypoxic areas” NCT00323076 ↗ |